Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human C-MYC Antibodies:
anti-Rat (Rattus) C-MYC Antibodies:
anti-Mouse (Murine) C-MYC Antibodies:
Go to our pre-filtered search.
Human Monoclonal C-MYC Primary Antibody for FM, IHC (fro) - ABIN967320
Blackwood, Eisenman: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. in Science (New York, N.Y.) 1991
Show all 13 Pubmed References
Human Monoclonal C-MYC Primary Antibody for FACS, IHC (p) - ABIN302017
Veracini, Simon, Richard, Schraven, Horejsi, Roche, Benistant: The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. in The Journal of cell biology 2008
Show all 15 Pubmed References
Human Monoclonal C-MYC Primary Antibody for FACS, IHC (p) - ABIN302092
Wang, Campoli, Ko, Luo, Ferrone: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. in Journal of immunological methods 2004
Show all 14 Pubmed References
Chicken Monoclonal C-MYC Primary Antibody for ChIP, CyTOF - ABIN152253
Locker, Dowle, Ellis, Elston, Blamey, Sikora, Evan, Robins: c-myc oncogene product expression and prognosis in operable breast cancer. in British journal of cancer 1989
Show all 10 Pubmed References
All Species Monoclonal C-MYC Primary Antibody for FACS, IP - ABIN2749043
Persson, Hennighausen, Taub, DeGrado, Leder: Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. in Science (New York, N.Y.) 1984
Show all 15 Pubmed References
All Species Monoclonal C-MYC Primary Antibody for IHC, IHC (p) - ABIN4994828
Hilpert, Hansen, Wessner, Küttner, Welfle, Seifert, Höhne: Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. in Protein engineering 2001
Show all 6 Pubmed References
Human Monoclonal C-MYC Primary Antibody for FACS, IHC (p) - ABIN4369572
Fujiwara, Poikonen, Aleman, Valtavaara, Saksela, Mayer: A single-chain antibody/epitope system for functional analysis of protein-protein interactions. in Biochemistry 2002
Show all 3 Pubmed References
Human Monoclonal C-MYC Primary Antibody for IHC (fro), IF - ABIN2477762
Quant, Woo: Normal values of eye position in the Chinese population of Hong Kong. in Optometry and vision science : official publication of the American Academy of Optometry 1992
Show all 4 Pubmed References
Human Monoclonal C-MYC Primary Antibody for IF, WB - ABIN3201011
Khanna, Böckelman, Hemmes, Junttila, Wiksten, Lundin, Junnila, Murphy, Evan, Haglund, Westermarck, Ristimäki: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. in Journal of the National Cancer Institute 2009
Show all 2 Pubmed References
Further analysis indicated that JQ1 inhibited the recruitment of BDR4 to the promoter complex of the Myc and Ccnd1 (show CCND1 Antibodies) genes in rat thyroid follicular PCCL3 cells, resulting in decreased MYC expression at the mRNA and protein levels to inhibit tumor cell proliferation
Data show that inhibition of sphingosine kinase-2 (show SPHK2 Antibodies) by ABC294640 is synergistically cytotoxic with gemcitabine toward three pancreatic cancer cell lines, resulting in decreased expression of both ribonucleotide reductase regulatory subunit M2 (RRM2 (show RRM2 Antibodies)) and c-MYC protein (Myc) in all three cell lines.
Data show that tripartite motif-containing protein 33 (TRIM33 (show TRIM33 Antibodies)) silencing attenuates down-regulation of MYC and TGF-beta (show TGFB1 Antibodies) signaling in response to bromodomain and extraterminal domain protein inhibitors (BETi).
C-MYC is related to GATA3 (show GATA3 Antibodies) and Ki-67 (show MKI67 Antibodies) expression and associated with poor prognosis in nodal peripheral T-cell lymphomas
Strong cytoplasmic c-myc expression and weak nuclear expression in adrenocortical tumours associated with malignancy and shorter survival.
MYC genetic heteroclonality is a frequent event in diffuse large B-cell lymphoma and may have a relevant role in modulating MYC expression.
MYC-nick, fascin (show FSCN1 Antibodies), and Cdc42 (show CDC42 Antibodies) are frequently up-regulated in cells present at the invasive front of human colorectal tumors, suggesting a coordinated role for these proteins in tumor migration.
Report differential expression of EZH2 (show EZH2 Antibodies) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 (show EZH2 Antibodies) expression by p-ERK1/2 (show MAPK1/3 Antibodies) and MYC in aggressive B-cell lymphomas.
Results strongly indicate that SCLC cells carrying amplification of MYC, MYCL or MYCN (show MYCN Antibodies) are addicted to MYC function.
Results revealed for the first time that glioblastoma exhibited differential MYC mediated transcriptional inhibition on MC-let-7a-1~let-7d due to the defective MYC/E-box3 binding.
Ouabain-induced proliferation might be attributed, at least in part, to decrease of intracellular free calcium and increase of c-myc mRNA expression, and that may be directly or indirectly involved in regulation of blood pressure.
report the isolation of complete coding regions of rabbit SOX2, KLF4, C-MYC and NANOG, which encode transcription factors that play crucial regulatory roles during early mammalian embryonic development
High c-myc expression is associated with gliomagenesis.
In a mouse lung model of KRas(G12D)-driven adenomas, co-activation of Myc drives the immediate transition to highly proliferative and invasive adenocarcinomas marked by highly inflammatory, angiogenic, and immune-suppressed stroma.
the role of phosphorylation on AID serine38 in AID activity at the Immunoglobulin switch region and off-target Myc gene, is reported.
This study demonstrates that LMP2A uses the role of MYC in the cell cycle, particularly in the p27(kip1 (show CDKN1B Antibodies)) degradation process, to accelerate lymphomagenesis in vivo.
Results show Myc to be dispensable for sustained in vivo hepatocyte proliferation but necessary for maintaining normal lipid homeostasis.
Data show that the induction of BIM (show BCL2L11 Antibodies) in the MYC- and RAS-driven leukemia is mediated by the downregulation of miR-17-92, and suggest that induction of BIM (show BCL2L11 Antibodies)-mediated apoptosis may be a therapeutic approach for acute lymphoblastic leukemia (ALL).
Pin1 (show PIN1 Antibodies) silencing in lymphomas retarded disease progression in mice, making Pin1 (show PIN1 Antibodies) an attractive therapeutic target in Myc-driven tumors.
beta-catenin (show CTNNB1 Antibodies) cooperates with the transcription factor Myc to activate the progenitor renewal program.
Gfi1 (show ZNF163 Antibodies) disruption antagonized the tumor-promoting effects of Ezh2 (show EZH2 Antibodies) loss; conversely, Gfi1 (show ZNF163 Antibodies) overexpression collaborated with Myc to bypass effects of Trp53 (show TP53 Antibodies) inactivation in driving medulloblastoma progression in primary cerebellar neuronal progenitors.
rather than via E-Box binding, cMyc acts in the dorsal neural tube by interacting with another transcription factor, Miz1 (show PIAS2 Antibodies), to promote self-renewal. The finding that cMyc operates in a non-canonical manner in the premigratory neural crest highlights the importance of examining its role at specific time points and in an in vivo context.
Apoptosis was also observed with myca expression; introduction of homozygous tp53 (show TP53 Antibodies)(-/-) mutation into the myca transgenic fish reduced apoptosis and accelerated tumor progression.
MYC down-regulation induces mitochondrial apoptosis in T lymphoblasts.
Thyroid hormone (show PTH Antibodies) activates protein arginine methyltransferase 1 expression by directly inducing c-Myc transcription during Xenopus intestinal stem cell development.(
c-Myc has a direct role in the control of DNA replication
Findings support a model in which Myc, Twist and Slug/Snail2 function in a regulatory circuit within lateral plate mesoderm that directs normal vessel formation in both the vascular and lymphatic systems.
tissue-specific downregulation of the Drosophila homolog of human c-myc proto-oncogene (dMyc) suppresses tau-mediated morphological and functional deficits by reducing abnormal tau hyperphosphorylation and restoring the heterochromatin loss.
dMyc has an essential role in preventing JNK (show MAPK8 Antibodies)-mediated retinal glial activation
the key target of the Psi/MED network in controlling developmentally regulated tissue growth is the transcription factor MYC.
Myc dosage plays crucial role in determining sex-specific size in Drosophila larvae and adult tissue. Double dose of Myc in females serves at least twice in development to promote sexual size dimorphism.
BicC (show BICC1 Antibodies) down regulates Myc in the Malpighian tubule.
activation of the TOR-Myc axis in midgut stem and progenitor cells influences a variety of traits in Drosophila
Drosophila adult muscle precursors display homing behavior to muscle niche and the niche-driven Insulin (show INS Antibodies)-Notch (show NOTCH1 Antibodies)-dMyc cascade plays a key role in setting the activated state of adult muscle precursors.
a functional link between Myc, a renowned oncogene (show RAB1A Antibodies), and the essential nucleotide biosynthetic enzyme CTPsyn.
MYC and S6K (show RPS6KB1 Antibodies) cooperate through coordinate activation of the essential Pol I transcription initiation factor TIF-1A (show RRN3 Antibodies).
The data demonstrate that dMYC repression and dMYC-dependent overgrowth in the Hfp hypomorph is further impaired in the C-terminal Hay/XPB (show GTF2H5 Antibodies) mutant background.
The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene.
avian myelocytomatosis viral oncogene homolog
, class E basic helix-loop-helix protein 39
, myc proto-oncogene protein
, myc-related translation/localization regulatory factor
, proto-oncogene c-Myc
, transcription factor p64
, v-myc myelocytomatosis viral oncogene homolog
, c-myc proto-oncogene
, avian myelocytomatosis viral (v-myc) oncogene homolog
, Avian myelocytomatosis viral (v-myc) oncogene homolog
, myelocytomatosis viral oncogene homolog
, v-myc avian myelocytomatosis viral oncogene homolog
, cellular myelocytomatosis oncogene
, Proto-oncogene c-Myc
, Transcription factor p64
, transcriptional regulator Myc-A
, MYC II
, transcriptional regulator Myc-B
, Myc proto-oncogene protein
, CG10798 gene product from transcript CG10798-RB
, Diminutive protein
, lethal (1) G0354
, lethal (1) G0359